Prev Close | 611.72 |
Open | 604.89 |
Day Low/High | 587.41 / 606.40 |
52 Wk Low/High | 583.05 / 973.16 |
Volume | 966.80K |
Prev Close | 611.72 |
Open | 604.89 |
Day Low/High | 587.41 / 606.40 |
52 Wk Low/High | 583.05 / 973.16 |
Volume | 966.80K |
Exchange | NYSE |
Shares Outstanding | 151.50B |
Market Cap | 90.69B |
P/E Ratio | 23.08 |
Div & Yield | N.A. (N.A) |
Upside - +49% (confirms to be acquired by Halozyme at $5.60/shr in $960M all-cash deal) - +38% (to be acquired for $55.00/shr in cash by GlaxoSmithKline in $1.9B deal) - +11% (strength ahead of Needham conference presentation) - +5.7% (earnings, gu...
We're probably not that far off from another bear market rally. That said, trading this market is going to be like doing the booby trap course at Camp Lejeune at night.
Here's what traders should continue to avoid.
Let's see how this earnings season shapes up.
* The asymmetry of Federal Reserve policy responses and the misguided fiscal/regulatory actions are joined at the hip * It remains my view that inflation will be far stickier and more elevated than the consensus expects * The conflict between Russia...
Why are people buying stocks against the backdrop of the biggest European conflict since 1945?
A firestorm over investor Chamath Palihapatiya's comments are calling attention to a big blind spot many billionaires seem to have on Beijing.
Don't ever let a single-modality outlook cloud your investing behavior. It's a great big world out there.
BlackRock posted better-than-expected results, but we care about the charts more.
Plus, many economists don't seem to understand the term "full employment" and earnings season kicks off.
Yes, volatility beckons. I hear it too. There may be a revaluation of equities across the board in 2022.
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
With Tesla's out-of-this-world valuation, recent IPO pops, advances by Apple, and potential 'old auto' dark horses, are we watching a bubble ... or something else?
Paytm shares plunged 27% on debut day, which stands in stark contrast to other stellar tech initial public offerings in India.
There probably will be an intense period of market volatility that could stretch farther out than even I projected a couple of months ago.
The charts appear positive so far for BLK.
We live in an age of information overload and bias. Here's where I go to stay informed to make good decisions.
There are homes that could house an urban population of around 4 million now under construction by Evergrande alone.
Like spilled milk, there is no use in crying over lost monetary opportunity that only increases economic risk at a bad time fiscally now.
Let's take a look at the war of words on China investment between these two billionaires.
The broad Chinese property sector, the mainland's largest single industry, is selling off in Hong Kong as investors try to work out which will be the next domino to fall.
While most tend to think of the S&P 500, the Dow and the Nasdaq when assessing how the "market" is performing year to date or even quarter to date, it's fair to say that those index or benchmarks haven't kept up all that well with the evolution of c...
Plus, taking another look at Robinhood post-IPO and what it says about the modern marketplace.
The Russell 2000 is now down not just back-to-back sessions, but six sessions in the last eight with all six of those "down" days having given up 0.9% or more.
If you are not in the market for a vehicle right now, inflation is right where the pros thought it would be.
Shares of BLK have delivered strong gains with more likely ahead.
But instead of complaining about -- or even worse, ignoring -- price spikes, invest in them.
Let's look at XOM's management, why it just lost a couple board seats and what I see ahead.